Navigation Links
Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
Date:5/1/2008

HONG KONG, May 1 /PRNewswire/ -- The clinical impact of the first-ever pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, is the subject of a symposium at next month's 16th Annual Scientific Congress of the Hong Kong College of Cardiology.

Scheduled for May 3 at the Sheraton Hong Kong Hotel, the one-hour session will include:

-- An opening address by the symposium's chairperson, Tak Fu Tse, M.D., of

the Hong Kong Sanatorium & Hospital, Hong Kong, from 1:30 p.m.-1:35 p.m.

-- The latest clinical update on the Genous technology by Federico

Piscione, M.D., of Federico II University, Naples, from 1:35 p.m.-1:55

p.m.

-- A presentation about the selection of stents in AMI patients by Harry

Suryapranata, M.D., of Isala Klinieken, Zwolle, The Netherlands, from

1:55 p.m.-2:15 p.m.

-- A Q&A session followed by closing remarks from Dr. Tse from 2:15 p.m.-

2:30 p.m.

"Based on the data we've seen with the real-world use of Genous and in recent clinical trials, we believe that the stent is an important alternative to drug-eluting stents," said Dr. Tse. "The stent's safety profile and the minimal requirements for dual antiplatelet therapy following placement can have a significant clinical impact, especially in patients who are likely to bleed or require surgery in the near future."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includ
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Newswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: ...mmitted to discovering, developing and commerciali...ed financial results for the fiscal year ended Sep...held $58.4 million in cash, cash equivalents and s... 2009 Highlights ,, RG7128 ,, Phase 2b ...
(Date:11/25/2009)...ire/ -- BioTrends Research Group, Inc. released Wa...rt, the first in a multi-phase syndicated market r...tho-Biotech,s Stelara, from product launch through...of the report provides quantitative information fr...ation from a subset of 20. The reports assess tri...
(Date:11/25/2009)... Remedium Technologies I...m that stops severe bleeding, won first prize and ...ry of the Global Security Challenge 2009, company ... than 100 entries from around the world, Remedium,... Summit conference held at the London School of Bu...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3AIDS is DCs Katrina Ad Challenges Obama to Act on U S Epidemic 47716 1AIDS is DCs Katrina Ad Challenges Obama to Act on U S Epidemic 47716 2AIDS is DCs Katrina Ad Challenges Obama to Act on U S Epidemic 47716 3AIDS is DCs Katrina Ad Challenges Obama to Act on U S Epidemic 47716 4NuVasive to Present at the 2009 William Blair Growth Stock Conference 47711 1NuVasive to Present at the 2009 William Blair Growth Stock Conference 47711 2NuVasive to Present at the 2009 William Blair Growth Stock Conference 47711 3Gains on Uninsured Reducing Shortages of Nurses Physicians Health Care Funding Among Sessions Successes 47706 1Gains on Uninsured Reducing Shortages of Nurses Physicians Health Care Funding Among Sessions Successes 47706 2Gains on Uninsured Reducing Shortages of Nurses Physicians Health Care Funding Among Sessions Successes 47706 3Gains on Uninsured Reducing Shortages of Nurses Physicians Health Care Funding Among Sessions Successes 47706 4
...DUBLIN, Calif., April 15 SuperGen Inc.,(Nasdaq: ...discovery, rapid,development and commercialization...alignancies, today announced as part of a series o...at MP-470, its,clinical-stage multi-targeted tyros...vailable and safe in humans (Abstract No. 4083)., ...
...-No Metastatic Lesions Were Detectable After Combi...n Doubled in Animals Treated with Combination ...Tumors Regressed by 50% After Combination Therapy ...5 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ...loping targeted monoclonal antibodies for the,trea...
Other Medicine Technology:Data Show SuperGen's MP-470 is Safe in Humans 2Data Show SuperGen's MP-470 is Safe in Humans 3Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer 2Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer 3Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer 4Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer 5
(Date:11/29/2009)...l Dentistry (AGD) announces that Aria Irvani, DDS,...d during the AGD,s commencement celebration that r... dental education.,To accomplish this, Dr. Irvani...al education in the 16 disciplines of dentistry, i...d techniques. , (PRWEB) N...
(Date:11/29/2009)...ds to more self-defensive finger pointing, study f...) -- The blame game is a contagious one, a new stu... Researchers found that when people see someone bl...fair accusation, they,re much more likely to engag...s protecting their egos, we become defensive, too....
(Date:11/29/2009)...e,s uncertain future and rising costs open the doo...le Acupuncture Scottsdale answers the call. , ...Affordable Acupuncture, LLC opened in Scottsdale i...nthusiasm and gratitude. Its increasing popularity..., need and cost. "As far as I’m concer...
(Date:11/28/2009)...ircadian rhythm, , , FRIDAY, Nov. 2...n internal body clock that goes on the fritz could...r in children. , The finding results from the ...with bipolar disorder, which can make people susce...out the disorder. They linked variations in a gene...
(Date:11/27/2009)...s Ltd. today issued its latest biochemical analysi...he lethality of the virus has dropped from its pea...break in the spring of 2009 to resting non-epidemi...ectivity count, however, remains increased. , ...009 -- Biotech firm Replikins Ltd., which has anal...
Breaking Medicine News(10 mins):Health News:Orange County Dentist Honored by The Academy of General Dentistry 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5
...respected and renowned Smoking Cessation Specialis...a breakthrough hypnosis technique to quit smoking ...Los Angeles, CA (PRWEB) August 15, 2006 -- Franc T...ual hypnotherapy session. , , , , ,Tausch, an in...
...ic, report finds , , MONDAY, April 6 (Heal...garette smoking are well known, but researchers ha...the United States. , The examination of intermitte...d in a series of studies and articles in a special...
...difies the androgen receptor (AR) and influences i...e progression of prostate cancer. The research, pu...e journal Cancer Cell , may also drive creation o...nt mediator for the development and progression of...
...o receive accreditation , , GREEN BAY, Wis., Ap... first four hospitals in the country to be accredi...st Centers (NAPBC), administered by the American C...78204LOGO-b ) , , "This is an outstanding achieve...
...ionally , , OKLAHOMA CITY, April 6 Christian ...are franchise to combine practical and spiritual a... of Oklahoma. A location in Cordova, Tenn. is sche...f communications. "Since August of last year, we h...
...(AIM: CRW.L), the healthcare industry,s trusted ma...utions, announced an agreement with Premier Purc...f Premier Inc. Under the agreement, Premier Purch... and client hospitals and more than 54,000 other h...
Other Medicine News:Health News:Hypnotherapy Breakthrough: Renowned Smoking Cessation Specialist Helps To Stop Smoking In One Session 2Health News:Researchers Profile the 'Light' Smoker 2Health News:A potential new target for treatment of hormone refractory prostate cancer 2Health News:Aurora BayCare is Wisconsin's First Nationally Accredited Breast Program 2Health News:Craneware to Offer Financial Performance Solutions to Hospitals and Healthcare Providers Through Premier, the Largest U.S. Healthcare Alliance 2Health News:Craneware to Offer Financial Performance Solutions to Hospitals and Healthcare Providers Through Premier, the Largest U.S. Healthcare Alliance 3
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: